News & Analysis on Clinical Trial Services & Contract Research And Development
Scientists have discovered a potential new drug target that will prick up the ears of sportsmen and athletes alike. Not that this is an performance-enhancing drug; instead, it could help athletes recover from injury more quickly.
MDS Pharma is continuing its efforts to move on from the trouble caused in its Pharma Services segment by a US Food and Drug Administration (FDA) review of its Montreal-area bioanalytical facilities.
Microarray expert Affymetrix is to buy molecular biology reagent firm USB Corporation for $75m (€52m) in a bid to accelerate the development of new genetic analysis tools.
UK-based William Ransom & Son has a shaky future ahead following a disappointing and unacceptable six-month financial report, compounded by a suspension of the companys manufacturing license.
Biopartners has terminated its supply agreement with The Medical House because of a go-slow in receiving functional drug delivery devices.
Eli Lilly, Shire, Pregis, and Eisai have all had people on the move in the world of pharmaceutical manufacturing.
Merck & Co. has just inked "multi-million dollar" deal with Cognizant, at a time when the US-based IT services firm is pursuing a greater presence in the life sciences sector.
Pfizer, the world's largest pharma firm, has reached into its pockets to buy CovX, a privately-held US biotech that specialises in combining the strengths of peptides and antibodies into new drugs.